scholarly journals The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0198771 ◽  
Author(s):  
Xuesong Han ◽  
Jingxuan Zhao ◽  
Kathryn J. Ruddy ◽  
Chun Chieh Lin ◽  
Helmneh M. Sineshaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Young Women ◽  
Affordable Care Act ◽  
Breast Cancer Treatment ◽  
Coverage Expansion ◽  
The Affordable Care Act ◽  
Dependent Coverage ◽  
The Impact

scholarly journals Association Between the Affordable Care Act Dependent Coverage Expansion and Cervical Cancer Stage and Treatment in Young Women

JAMA ◽  
2015 ◽  
Vol 314 (20) ◽  
pp. 2189 ◽  
Author(s):  
Anthony S. Robbins ◽  
Xuesong Han ◽  
Elizabeth M. Ward ◽  
Edgar P. Simard ◽  
Zhiyuan Zheng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Young Women ◽  
Affordable Care Act ◽  
Cancer Stage ◽  
Coverage Expansion ◽  
The Affordable Care Act ◽  
Dependent Coverage

scholarly journals The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mads G. Jørgensen ◽  
Navid M. Toyserkani ◽  
Frederik G. Hansen ◽  
Anette Bygum ◽  
Jens A. Sørensen
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.

Breast Cancer Stage at Presentation in Ohio: The Effect of Medicaid Expansion and the Affordable Care Act

2020 ◽  
Vol 86 (3) ◽  
pp. 195-199
Author(s):  
Dan Kirkpatrick ◽  
Margaret Dunn ◽  
Rebecca Tuttle
Keyword(s):  
Breast Cancer ◽  
Affordable Care Act ◽  
Advanced Disease ◽  
Disease Stage ◽  
Cancer Stage ◽  
Medicaid Expansion ◽  
Cancer Data ◽  
Before And After ◽  
The Affordable Care Act ◽  
The Impact

Patients presenting with localized breast cancer have a five-year survival of 99 per cent, whereas survival falls to 27 per cent in advanced disease. This obviates the importance of early diagnosis and treatment. Our study evaluates the impact of Ohio's Medicaid expansion and the passage of the Affordable Care Act (ACA) on the stage at which Ohioans were diagnosed with breast cancer. Data were collected for 3056 patients presenting with breast cancer between 2006 and 2016 in the Dayton area. Patients were divided into groups based on cancer stage. The percentage of patients presenting with advanced disease (stage 3 or 4) was compared both before and after ACA implementation and Ohio Medicaid expansion. These results were also compared with statewide data maintained by the Ohio Department of Health. Compared with pre-ACA, the number of uninsured patients post-ACA was noted to fall 83 per cent, the number of patients presenting with Medicaid increased by five times, and the proportion of patients younger than 65 years presenting with breast cancer increased by approximately 7 per cent. These changes notwithstanding, no difference was identified in the percentage of patients presenting with advanced breast cancer before and after ACA implementation or Ohio Medicaid expansion ( P = 0.56). Statewide data similarly demonstrated no change ( P = 0.88). Improved insurance access had a smaller-than-anticipated impact on the stage at which Ohioans presented with breast cancer. As significant morbidity and mortality can be avoided by earlier presentation, additional research is appropriate to identify factors affecting patients’ decision to seek breast cancer screening and care.

77 The impact of the boost type (E−, IR-192 HDR) on the cosmetic result in conservative breast cancer treatment

1994 ◽  
Vol 31 ◽  
pp. S41 ◽  
Author(s):  
J. Hammer ◽  
C. Track ◽  
B. Pakisch ◽  
D.H. Seewald ◽  
J.P. Zoidl ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Cosmetic Result ◽  
The Impact

scholarly journals St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment

Breast Care ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. 103-110 ◽  
Author(s):  
Marija Balic ◽  
Christoph Thomssen ◽  
Rachel Würstlein ◽  
Michael Gnant ◽  
Nadia Harbeck
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Patient Empowerment ◽  
Breast Cancer Treatment ◽  
Consensus Conference ◽  
Great Success ◽  
Main Theme ◽  
Treatment Standards ◽  
The Impact

This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17–20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Consensus votes’ challenge was to define the impact on routine everyday practice. This year, the conference’s main theme was the optimization of early breast cancer therapies by assessment of the magnitude of benefit, aiming at further refinement when compared to de-escalation and escalation, which were mainly the topic of the 2017 conference. Patient empowerment and the importance of shared decision-making were particularly emphasized. The traditional panel votes were moderated by Eric Winer from Harvard, and for the most part, they managed to clarify most of the critical questions. This brief report by Editors of Breast Care summarizes the results of the 2019 international panel votes with respect to locoregional and systemic treatment as a quick news update for our readers, but it expressly does not intend to replace the official St. Gallen Consensus publication that will follow shortly in Annals of Oncology.

The Impact of Facility Volume/Size on Breast Cancer Treatment and Outcome

2010 ◽  
Vol 76 (12) ◽  
pp. 1333-1337 ◽  
Author(s):  
Jack Sariego
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Definitive Treatment ◽  
Treatment Facility ◽  
Cancer Data ◽  
Stage Distribution ◽  
Significant Difference ◽  
The Impact

Recent studies have suggested that outcomes and survival from breast cancer are improved when definitive treatment is rendered at high-volume and/or teaching centers. Consolidation of such cases in tertiary centers, however, is often impractical and impossible. Patients often desire primary treatment of their breast cancer in their own communities. The current study was undertaken to examine the impact of treatment facility type on the treatment performed as well as on overall survival. Breast cancer treatment and survival data were available from the American College of Surgeons National Cancer Data Base. Only patients in whom no previous treatment had been rendered were included in the analysis. Data were stratified with regard to type and size of treatment facility/hospital; stage distribution; initial treatment performed; and 1-, 2-, and 5-year survival. A total of 665,409 patients were included in the current analysis. There were no significant differences in stage distribution between facility types nor was there a significant difference in the treatment performed (although there was a slight trend toward breast conservation at the larger centers). This was true overall and for each stage of cohort. There were also no significant differences in 1-, 2-, and 5-year survival rates overall and at any stage (although again, there was a slight trend toward a minimal survival advantage at the larger centers). There was no significant impact of facility size or type on either breast cancer treatment performed or overall survival. There was no evidence that more “advanced” treatments were offered at larger centers nor was there evidence of improved outcome/survival at larger centers. Care can be rendered safely, efficiently, and effectively in the community setting.

Sign in / Sign up

Export Citation Format

Share Document